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Background
Wild-type TTR amyloidosis (wt-ATTR) is a common
aging phenomenon in the elderly population. It is
claimed to affect exclusively males. Female gender was
assumed as a protective factor. Clinical data on
wt-ATTR in female gender is lacking. This single center
analysis reported on gender differences of clinical vari-
ables in wt-ATTR.
Methods
Patient records of 207 consecutive patients with
wt-ATTR were analyzed for clinical variables obtained
during the initial assessment at Heidelberg Amyloidosis
Center, including electrocardiography, echocardiography,
and laboratory results. All variables were compared
between male and female gender. Finally, predictors
of survival (onset of first symptoms to death) were
evaluated.
Results
Comparison of clinical findings between males and
females affected by wt-ATTR amyloidosis are shown in
table 1. Female patients with wt-ATTR did not differ
from male patients regarding demographic or clinical
parameters except for modified body mass index
(1140±184 vs. 1029±154, p<0.05), glomerular filtration
rate (66±23 vs. 85±31 ml/min*m2*1.73; p<0.05), NYHA
class (2.4±0.7 vs. 2.9±0.3; p<0.01) and PQ interval
(211±50 ms vs. 170±26; p<0.01). Interestingly, both
groups especially did not differ in age at onset of symp-
toms, but longer delay between start of symptoms and
diagnosis of wt-ATTR in females was observed when
compared to male patients with wt-ATTR.
In total, 6 deaths (35%) occurred in females and 45
deaths (24%) in males. No gender differences were
observed regarding mean survival (females 54±35
month, males 56±107 months). By multivariate analysis
independent predictors of mortality in the whole cohort
were use of diuretics (HR 8.657, 95%CI 1.160-64.17;
p=0.035) and hs-TnT (HR 1.009, 95%CI 1.004-1.015;
p=0.001).
In total, 6 deaths (35%) occurred in females and 45
deaths (24%) in males. No gender differences were
observed regarding mean survival (females 54±35
month, males 56±107 months). By multivariate analysis
independent predictors of mortality in the whole cohort
were use of diuretics (HR 8.657, 95%CI 1.160-64.17;
p=0.035) and hs-TnT (HR 1.009, 95%CI 1.004-1.015;
p=0.001).
Conclusion
Although wt-ATTR is claimed to be a disease of male
gender there is a considerable number of females affected
with cardiac manifestation of wt-ATTR. According to
this first report on clinical characteristics of a relatively
well sized cohort of females no gender-specific differ-
ences regarding clinical characteristics and median survi-
val were observed, except for modified body mass index
and PQ interval as well as higher glomerular filtration
rate and NYHA class in female patients. Moreover, use of
diuretics and hs-TnT appeared to be predictors of
mortality.
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